Berlex Foundation Seeks Workshop Applicants

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 5
Volume 5
Issue 5

DUMONT, NJ--The Berlex On-cology Foundation is seeking applicants for two workshops: Epidemiology and Clinical Trial Design, to be held August 23-29, 1996, in Brewster, Mass, and The Clinical Pharmacology of Anticancer Drugs, which will take place October 4-8, 1996, in Leesburg, Va.

DUMONT, NJ--The Berlex On-cology Foundation is seeking applicantsfor two workshops: Epidemiology and Clinical Trial Design, tobe held August 23-29, 1996, in Brewster, Mass, and The ClinicalPharmacology of Anticancer Drugs, which will take place October4-8, 1996, in Leesburg, Va.

Aimed at young investigators interested in cancer research, theinteractive workshops offer ample opportunity for one-on-one interfacingwith the faculty, as well as peer-to-peer networking.

The awards cover travel expenses, lodging, meals, course syllabus,and textbooks. The application deadlines are May 30, 1996, forthe epidemiology workshop, and June 30, 1996, for the anticancerdrugs course. Twenty scholars will be selected for each program.

All applicants must be currently enrolled in an accredited oncologytraining program and should possess a demonstrated interest incancer research. Applicants must supply a current curriculum vitae,letter of recommendation from the department chairman, and a one-pageletter describing the applicant's purpose in attending the program.

For more information, contact Svetlana Lisanti, Berlex OncologyFoundation, 80 W. Madison Ave., Dumont, NJ 07628, or telephone201-385-0006.

Recent Videos
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
Data from the phase 3 DeLLphi-304 trial at ASCO 2025 revealed a survival advantage with tarlatamab vs chemotherapy in second-line ES-SCLC.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
The FDA approval of tarlatamab in SCLC has received much press attention, according to Daniel R. Carrizosa, MD, MS.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
A combined cohort composed of patients from the TROPION-Lung01 and TROPION-Lung-05 trials showed a survival advantage with dato-DXd vs docetaxel.
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
4 experts in this video
Related Content